Dave L. Roelen

8.8k total citations
207 papers, 6.1k citations indexed

About

Dave L. Roelen is a scholar working on Immunology, Transplantation and Surgery. According to data from OpenAlex, Dave L. Roelen has authored 207 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Immunology, 88 papers in Transplantation and 47 papers in Surgery. Recurrent topics in Dave L. Roelen's work include Renal Transplantation Outcomes and Treatments (83 papers), T-cell and B-cell Immunology (65 papers) and Immune Cell Function and Interaction (46 papers). Dave L. Roelen is often cited by papers focused on Renal Transplantation Outcomes and Treatments (83 papers), T-cell and B-cell Immunology (65 papers) and Immune Cell Function and Interaction (46 papers). Dave L. Roelen collaborates with scholars based in Netherlands, United Kingdom and United States. Dave L. Roelen's co-authors include Frans H.J. Claas, Sicco A. Scherjon, Ilias I.N. Doxiadis, Tamara Tilburgs, Sebastiaan Heidt, Barbara J. van der Mast, Humphrey H.H. Kanhai, Cees van Kooten, Arend Mulder and Geert W. Haasnoot and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Dave L. Roelen

196 papers receiving 6.0k citations

Peers

Countries citing papers authored by Dave L. Roelen

Since Specialization

Citations

This map shows the geographic impact of Dave L. Roelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dave L. Roelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dave L. Roelen more than expected).

Fields of papers citing papers by Dave L. Roelen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dave L. Roelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dave L. Roelen. The network helps show where Dave L. Roelen may publish in the future.

Co-authorship network of co-authors of Dave L. Roelen

This figure shows the co-authorship network connecting the top 25 collaborators of Dave L. Roelen. A scholar is included among the top collaborators of Dave L. Roelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dave L. Roelen. Dave L. Roelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Repeated HLA ‐ DRB1 and HLA ‐ DQB1 Mismatches Without Preformed DSA Affect Graft Survival, Rejection and DSA Development: A Multicenter Analysis 2025 ·HLA ·(unknown), Soufian Meziyerh, Danny van der Helm, (unknown), Jan‐Stephan Sanders, (unknown), Jacqueline van de Wetering, (unknown), Jesper Kers, Cees van Kooten, Joris I. Rotmans, Aiko P. J. de Vries, Dave L. Roelen	1
2	Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 6 vs. 3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dave L. Roelen, (unknown), (unknown), (unknown)	0
3	Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided? 2024 ·Frontiers in Genetics ·(unknown), Pauline Erpicum, (unknown), (unknown), Marlies E. J. Reinders, Soufian Meziyerh, Dave L. Roelen, Johan W. de Fijter, Jesper Kers, Laurent Weekers, Y Beguin, François Jouret, Sebastiaan Heidt	0
4	The detrimental effect of donor-specific antibodies is irrespective of its level in highly-immunized living donor kidney transplant recipients: A case-control series 2023 ·Frontiers in Immunology ·(unknown), Dave L. Roelen, (unknown), Judith A. Kal-van Gestel, Marcia M. L. Kho, Marlies E. J. Reinders, Joke I. Roodnat, Jacqueline van de Wetering, Michiel G.H. Betjes, Annelies E. de Weerd	4
5	Multiomic profiling of transplant glomerulopathy reveals a novel T-cell dominant subclass 2023 ·Kidney International ·(unknown), (unknown), (unknown), (unknown), (unknown), Thierry P. P. van den Bosch, Carla C. Baan, Dennis A. Hesselink, Rafael Kramann, Robert C. Minnee, Dana A. M. Mustafa, Marlies E. J. Reinders, Dave L. Roelen, (unknown), R. Neal Smith, Andrew Stubbs, Robert B. Colvin, Ivy A. Rosales, Marian C. Clahsen‐van Groningen	16
6	Local administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis 2023 ·JCI Insight ·(unknown), Marieke C. Barnhoorn, Hein W. Verspaget, (unknown), (unknown), Károly Szuhai, Lukas J.A.C. Hawinkels, Melissa van Pel, Jaap Jan Zwaginga, Dave L. Roelen, Frits Koning, María Fernanda Pascutti, Andrea E. van der Meulen‐de Jong	7
7	A modeling approach for mean fluorescence intensity value harmonization and cutoff prediction for luminex single antigen bead assays of two different vendors 2023 ·HLA ·Gonca E. Karahan, Geert W. Haasnoot, (unknown), Frans H.J. Claas, Dave L. Roelen, Sebastiaan Heidt	5
8	HLA‐DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor‐specific antibody formation after mesenchymal stromal cell therapy 2023 ·HLA ·(unknown), Soufian Meziyerh, Marlies E. J. Reinders, (unknown), (unknown), Dave L. Roelen, Jesper Kers, Johan W. de Fijter, Sebastiaan Heidt	7
9	Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study 2021 ·American Journal of Transplantation ·Marlies E. J. Reinders, (unknown), Sanne H. Hendriks, (unknown), (unknown), Aiko P. J. de Vries, Melissa van Pel, Helene Roelofs, Volkert A.L. Huurman, Pauline Meij, Dirk Jan A. R. Moes, Willem E. Fibbe, Frans H.J. Claas, Dave L. Roelen, Cees van Kooten, Jesper Kers, Sebastiaan Heidt, Ton J. Rabelink, Johan W. de Fijter	30
10	Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study 2020 ·American Journal of Transplantation ·(unknown), (unknown), Sebastiaan Heidt, Dave L. Roelen, Melissa van Pel, Helene Roelofs, Volkert A.L. Huurman, Ingeborg M. Bajema, Dirk Jan A. R. Moes, Willem E. Fibbe, Frans H.J. Claas, Cees van Kooten, Ton J. Rabelink, Johan W. de Fijter, Marlies E. J. Reinders	34
11	Low incidence of IgA isotype of HLA antibodies in alloantigen exposed individuals 2020 ·HLA ·(unknown), Gonca E. Karahan, (unknown), (unknown), Aiko P. J. de Vries, Cees van Kooten, Cynthia S. M. Kramer, Dave L. Roelen, Frans H.J. Claas, Sebastiaan Heidt	2
12	Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR 2020 ·American Journal of Transplantation ·Cynthia S. M. Kramer, (unknown), (unknown), (unknown), Gonca E. Karahan, Dave L. Roelen, Frans H.J. Claas, Sebastiaan Heidt	22
13	Maternal and child human leukocyte antigens in congenital cytomegalovirus infection 2018 ·Journal of Reproductive Immunology ·Roberta Rovito, Frans H.J. Claas, Geert W. Haasnoot, Dave L. Roelen, Aloys C.M. Kroes, Ann C.T.M. Vossen	2
14	Donor‐specific anti‐HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation 2017 ·Clinical Transplantation ·(unknown), Xiaolei Shi, Cornelia J. Verhoeven, Jeroen Dubbeld, Frans H.J. Claas, Ron Wolterbeek, (unknown), Hein W. Verspaget, Arantza Fariña Sarasqueta, Luc J. W. van der Laan, Herold J. Metselaar, Bart van Hoek, Jaap Kwekkeboom, Dave L. Roelen	17
15	Early Onset Acute Antibody Mediated Rejection (ABMR) Is More Common in Female Than in Male Recipients of a Living Unrelated Donor (LURD) Renal Transplant and Is Associated with the Presence of Preformed Donor Specific Antibodies (DSA). 2016 ·American Journal of Transplantation ·Darius Soonawala, (unknown), (unknown), Sebastiaan Heidt, Dave L. Roelen, Frans H.J. Claas, Johan W. de Fijter	2
16	Diagnosis of Early Pancreas Graft Failure via Antibody-Mediated Rejection: Single-Center Experience With 256 Pancreas Transplantations 2014 ·American Journal of Transplantation ·Hanneke de Kort, Marko J.K. Mallat, Cees van Kooten, Emile de Heer, (unknown), A M van der Wal, Candice Roufosse, Dave L. Roelen, Jan A. Bruijn, Frans H.J. Claas, Johan W. de Fijter, Ingeborg M. Bajema	17
17	Treatment of Renal Transplant Patients with Autologous Bone Marrow Derived Mesenchymal Stromal Cells Downregulates the Donor Specific Mixed Lymphocyte Reaction 2013 ·American Journal of Transplantation ·Marlies E. J. Reinders, Johan W. de Fijter, Helene Roelofs, Daniel H. de Vries, (unknown), (unknown), Dave L. Roelen, Cees van Kooten, Ton J. Rabelink	1
18	B-Cell Repopulation after Antithymocyte Globulin Compared with Anti-IL2 Receptor Induction: Increase in Transitional B Cells and BAFF Serum Levels 2013 ·American Journal of Transplantation ·Renaud Snanoudj, Sophie Candon, Dave L. Roelen, F.H.J. Claas, (unknown), Lucienne Chatenoud	1
19	Allo-HLA reactivity of virus-specific memory T cells is common 2010 ·Blood ·Avital L. Amir, Lloyd D’Orsogna, Dave L. Roelen, Marleen M. van Loenen, Renate S. Hagedoorn, Renate de Boer, Menno A. W. G. van der Hoorn, Michel G.D. Kester, Ilias I.N. Doxiadis, J.H. Frederik Falkenburg, Frans H.J. Claas, Mirjam H.M. Heemskerk	231
20	Comparison of Macrophage Phenotype Between Decidua Basalis and Decidua Parietalis by Flow Cytometry 2008 ·Placenta ·Urška Repnik, Tamara Tilburgs, Dave L. Roelen, Barbara J. van der Mast, Humphrey H.H. Kanhai, Sicco A. Scherjon, Frans H.J. Claas	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact